FDA Urged to Heed Advisory Committee’s Advice to Reject Animal Drug Linked to Antibiotic Resistance in Humans
Drug Manufacturer Vows to ‘Continue to Pursue Approval Activities’
Contact: Dan Klotz, 917-438-4613, 347-307-2866 (cell), dklotz@mrss.com
WASHINGTON, Nov. 2 /U.S. Newswire/ — The U.S. Food and Drug Administration (FDA) is being urged to follow the recommendation of the FDA’s scientific advisory committee to reject the use of cefquinome for treating respiratory disease in cattle linked to antibiotic resistance in human medicine. Despite this negative recommendation, the drug’s manufacturer, Intervet, has not withdrawn its application — as is usually done after advisory committee rejections. In fact, “the company says it is convinced that cefquinome use in livestock will not create public health concerns…Intervet will continue to pursue approval activities.” (See full text of Intervet news release at http://www.anguselist.com/volume12/v12anguselist14.html ).
Cefquinome is a 4th generation cephalosporin, a class of drugs that is highly valued in human medicine as treatment for serious and life-threatening infections. Growing scientific evidence shows that use of antibiotics in poultry, swine and beef cattle that are identical or similar to important antibiotics used in human medicine promotes development and spread of antibiotic- resistant bacteria that can be transferred to people via air, food, soil and water, making it harder to treat infections in humans.
“The FDA’s handling of scientific advice is under increasing public scrutiny, with critics alleging the agency sometimes gives

